FGFR4 and hepatocellular carcinoma: This mechanism is potentiated by fibroblast growth factor receptor 4 (FGFR4), and targeting IGF2BP1 in conjunction with anti-PD-L1 therapy can inhibit the proliferation and invasion of HCC cells [339, 340].